Title: Clinical value of botulinum toxin in neurological indications
Authors: Ward, A B ×
Molenaers, Guy
Colosimo, C
Berardelli, A #
Issue Date: Dec-2006
Publisher: Rapid Communications
Series Title: European journal of neurology vol:13 pages:20-26
Abstract: Botulinum toxin type-A (BoNT-A) prevents the release of acetylcholine at cholinergic junctions, thereby causing temporary muscle weakness lasting 3-4 months. It is now widely used to treat a broad range of clinical disorders characterized by muscle hyperactivity. BoNT-A has proved effective in the management of several neurological conditions and, in particular, in the management of movement disorders (e.g. blepharospasm, cervical dystonia, laryngeal dystonia, limb dystonia, hemifacial spasm, focal tics, tremor and other hyperkinetic disorders). As a treatment of spasticity, BoNT-A can improve mobility and dexterity as well as preventing the development of distressing and costly secondary complications. In cerebral palsy, BoNT-A is of value, being able to delay or even avoid surgery until motion patterns have become established.
ISSN: 1351-5101
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Orthopaedics Section (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science